Scientific Advances in Lung Cancer 2015

Cited by (285)

Items 201–285 of 285

1. A novel SLC8A1/LINC01913 intergenic region-ALK fusion identified by NGS and validated by IHC and FISH in a stage IIB lung adenocarcinoma patient who remains relapse-free during the treatment of crizotinib: a case report
   Chunguang Wang, Shu Chen, Qianru He, Tingting Sun, Peiran Xu · 2022 · Investigational New Drugs
2. Molecular Diagnosis and Targeting for Lung Cancer
   Kazue Yoneda, Fumihiro Tanaka · 2017 · Current human cell research and applications
3. A novel application of drug-eluting transarterial chemoembolization in treating non-liver cancers
   Zhen Li, Kun Ji, Liangliang Bai, Caihong Wang, Yingying Hu, Yang Shi, Pengchao Zhan, Lijie Song, Xin Li, Xuhua Duan et al. · 2020 · Medicine
4. Alectinib treatment response in lung adenocarcinoma patient with novel EML4‐ALK variant
   Peng Song, Jingcheng Zhang, Congcong Shang, Li Zhang · 2018 · Thoracic Cancer
5. Comprehensive analysis of genomic alterations detected by next‑generation sequencing‑based tissue and circulating tumor DNA assays in Chinese patients with non‑small cell lung cancer
   Hua Yang, Junjie Zhang, Lemeng Zhang, Xiaoping Wen, Yongzhong Luo, Dingquan Yao, Tianli Cheng, Huanqing Cheng, Huina Wang, Feng Lou et al. · 2019 · Oncology Letters
6. Preoperative CT features for prediction of ALK gene rearrangement in lung adenocarcinomas
   H. Wang, Y. Wang, H. Zhang, Ying Han, Q. Li, Zhimao Ye · 2020 · Clinical Radiology
7. Synchronal pulmonary sarcomatoid carcinoma and lung adenocarcinoma EML4‑ALK fusion: A case report
   Mingting Wang, Yifan Gong, Yun Cheng, Lei Yang, Wenhui Wang, Xiaolin Lei · 2022 · Oncology Letters
8. The Roles and Regulatory Mechanisms of Tight Junction Protein Cingulin and Transcription Factor Forkhead Box Protein O1 in Human Lung Adenocarcinoma A549 Cells and Normal Lung Epithelial Cells
   Daichi Ishii, Yuma Shindo, Wataru Arai, Takumi Konno, Takayuki Kohno, Kazuya Honda, Masahiro Miyajima, Atsushi Watanabe, Takashi Kojima · 2024 · International Journal of Molecular Sciences
9. Trends in Overall Survival in Lung Adenocarcinoma with EGFR Mutation, KRAS Mutation, or No Mutation
   Martin Faehling, Sabine Fallscheer, Birgit Schwenk, Harald Seifarth, Jörn Sträter, Claudia Lengerke, Petros Christopoulos · 2025 · Cancers
10. The “liquid biopsy” in non-small cell lung cancer—not quite ready for prime time use
    Angel Qin, Nithya Ramnath · 2016 · Translational Cancer Research
11. Applying bioethical principles for directing investment in precision medicine
    Alison Finall, Kerina Helen Jones · 2019 · Clinical Ethics
12. From Traditional Histology to Next-Generation Pathology: A Review of The Workflow for the Characterisation and Molecular Profiling of Non-Small Cell Lung Cancer Samples
    Umberto Malapelle, Nicola Fusco, Pasquale Pisapia, Fabio Pagni · 2020 · EMJ Oncology
13. A systematic review and meta-analysis of circulating cell-free DNA as a diagnostic biomarker for non-small cell lung cancer
    Xin He, Yaqian Chi, Jingcui Peng, Wenxia Hu, Cuimin Ding, Bin Li · 2022 · Journal of Thoracic Disease
14. The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual Symposium
    Nuria Viñolas, Laura Mezquita, Jesus Corral, Manuel Cobo, Francisco Gil, Luis G Paz-Ares, Jordi Remón, M. Fernández Rodríguez, Alberto Ruano‐Raviña, Esther Conde et al. · 2023 · Clinical & Translational Oncology
15. Performance characteristics of a polymerase chain reaction-based assay for the detection of EGFR mutations in plasma cell-free DNA from patients with non-small cell lung cancer using cell-free DNA collection tubes
    Theresa May, Michelle Simone Clement, Harkanwal Halait, Alexander Kohlmann, Milena Kohlmann, Jason Lai, Nitta Lee, Xiaocheng Li-Sucholeiki, Peter Meldgaard, Snehal S. Joshi et al. · 2024 · PLoS ONE
16. Molecular Dynamics of A Biglycan-Rosmarinic Acid Complex with Focal Adhesion Kinase for Possible Arrest of Metastasis in Non-Small Cell Lung Cancer (NSCLC): An In- Silico Study
    Hyacinth N. Highland, Monica Thakur, Pujan N. Pandya, Archana Mankad, Linz-Buoy George · 2019 · Journal of Drug Delivery and Therapeutics
17. [Progress on Mechanism of MET Gene Mutation and Targeted Drugs in Non-small Cell Lung Cancer].
    Sen Han, Xu Ma, Jian Fang · 2020 · PubMed Central
18. Biomarker landscape in advanced NSCLC: insights from a national prospective registry
    Mariano Provencio, Manuel Cobo, Delvys Rodríguez‐Abreu, Enric Carcereny, Virginia Calvo, Rafael López Castro, Reyes Bernabé, Manuel Fernandez Bruno, Joaquim Bosch‐Barrera, E. del Barco et al. · 2025 · Lung Cancer
19. Detection of Pulmonary Nodules in ct Images Using Deep Learning Technique
    Santhi Balachandran, divya divya divya, Nithya Rajendran, G.R. Brindha · 2020 · Journal of Computer Science
20. Construction and validation of a T cell proliferation regulator-related signature for predicting prognosis and immunotherapy response in lung adenocarcinoma
    Wuguang Chang, Hongmu Li, Yixin Cheng, Huanhuan He, Wei Ou, Siyu Wang · 2023 · Frontiers in Immunology
21. Kirsten Rat Sarcoma Mutation in South Indians with Non-Small Lung Cancer
    Gautam Balaram, Renjan Thomas, Suhas N. Ghorpade, Prarthana V. Kowsik, Baby Dharman, Yogesh Shivakumar, Shekar Gowda Patil, Satheesh Chiradoni Thungappa, H P Shashidhara, Somorat Bhattacharjee et al. · 2022 · Journal of Precision Oncology
22. Case report: Dissolving carotid plaque associated to Lorlatinib-related dyslipidemia
    Lukas Mayer‐Suess, Michael Knoflach, Andreas Pircher, Stefan Julia Kiechl, Christoph Schmidauer, Eva Hametner · 2024 · Frontiers in Oncology
23. Treatment Patterns and Clinical Outcomes Among Patients with Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations Previously Treated with Platinum-Based Chemotherapy and Immunotherapy
    Jerome H. Goldschmidt, Wan-Yu Tseng, Yunfei Wang, Janet L. Espirito, Anupama Vasudevan, Michelle Silver, Jackie Kwong, Ruchit Shah, Elizabeth Marrett · 2024 · Drugs - Real World Outcomes
24. Forced degradation of Ceritinib under stress conditions: Structural interpretation of novel degradants using HR-MS/MS and NMR
    Soujanya Vajjha, Vijay Bommuluri, Chidananda Swamy Rumalla, Muralidharan Kaliyaperumal, Raghu Babu Korupolu, Vidya Sagar Choppella · 2020 · Materials Today Proceedings
25. Increased AAA-TOB3 Correlates with Lymph Node Metastasis and Advanced Stage of Lung Adenocarcinoma
    Yanfeng Liu, Lina Bu, Wei Li, Wei Wu, Shengyu Wang, Xin Diao, Jing Zhou, Guoan Chen, Shuanying Yang · 2017 · The International Journal of Biological Markers
26. NOVAS TERAPIAS COM ALVO-MOLECULAR PARA O CÂNCER DE PULMÃO DE NÃO-PEQUENAS CÉLULAS
    Marcelo Augusto Martins Aires, Virgílio Ribeiro Guedes · 2018 · Revista de Patologia do Tocantins
27. Targeted Therapies in Non-small Cell Lung Cancer
    Jessica Ruth Bauman, Martin Joseph Edelman · 2022 · Medical radiology
28. Alk1 gene rearranged pulmonary sarcomatoid carcinoma masquerading as tuberculosis in a young male
    Ayushi Sahay, Rajiv Kumar, Amit Janu, Kumar Prabhash · 2020 · Turkish Journal of Pathology
29. Detecting therapy-guiding RNA aberrations in platelets of non-small cell lung cancer patients
    Pei Meng, Anna A. Rybczynska, Jiacong Wei, Miente Martijn Terpstra, Wim Timens, Ed M. D. Schuuring, T. Jeroen N. Hiltermann, Harry J.M. Groen, Anthonie J. van der Wekken, Anke van den Berg et al. · 2021 · medRxiv
30. Is there any prognostic significance in pleural involvement and/or effusion in patients with ALK-positive NSCLC?
    Gürkan Güner, Burak Yasin Aktaş, Fatma Buğdaycı Başal, Ahmet Demirkazık, Pınar Gürsoy, Umut Demırcı, Mustafa Erman, Perran Fulden Yumuk, Filiz Çay Şenler, Burcu Çakar et al. · 2023 · Journal of Cancer Research and Clinical Oncology
31. Molecular Markers, Immune Therapy, and Non-Small Cell Lung Cancer—State-of-the-Art Review for Surgeons
    Robert W.C. Young, Gustavo R. Rodriguez, John A. Kucera, Daniel Carrera, Jared L. Antevil, Gregory D. Trachiotis · 2024 · Journal of Laparoendoscopic & Advanced Surgical Techniques
32. Computed Topographic-Guided Core Needle Biopsy of Lung Masses: Our Experience at a Diagnostic Center in Western India
    Aniruna Dey, Sharma Anuj · 2020 · Journal of Medical Sciences and Health
33. Levels of APE1 Repair Gene and CLEC4M in Lung Cancer Patients Receiving Cisplatin Chemotherapy.
    Y M I Al-Mohammed Amin, Suhad Faisal Hatem Al-Mugdadi, Mohammed Mahmood Mohammed · 2023 · PubMed Central
34. Case report: SAF-189s is a potent inhibitor in a lorlatinib-resistant NSCLC patient with acquired compound mutations ALK L1196M and D1203N
    Na Li, Huihui Li, Ding Wang, Xiaoling Xu · 2023 · Frontiers in Pharmacology
35. Tabakentwöhnung – die bisher wenig genutzte Chance im ärztlichen Alltag
    Karin Vitzthum, Anil Batra, Wulf Pankow, Matthias Raspe, Alexander Rupp, Stefan Andreas · 2024 · DMW - Deutsche Medizinische Wochenschrift
36. Automatic Lung Nodules Detection Using a Modified YOLOv5
    Shital D. Bhatt, Mitesh B. Astik, Himanshu B. Soni · 2024 · Journal of biomimetics, biomaterials and biomedical engineering
37. Successful treatment of a non‐small‐cell lung cancer patient harboring HIP1 ‐ ALK ( H28 : A20 ) and CTNNB1 p.S45del with alectinib
    Vito Longo, Francesco Pesola, Rosanna Lacalamita, Annamaria Catino, Michele Montrone, Ilaria Marech, Pamela Pizzutilo, Elisabetta Sara Montagna, Stefania Tommasi, Domenico Galetta · 2024 · Thoracic Cancer
38. Real-World Data on Metastatic Lung Cancer: Cost Analyses in Brazil From a Private Insurance Company's Perspective
    Rodrigo Afonso da Silva Sardenberg, Mariana Ribeiro Monteiro, Cinthia Leite Frizzera Borges Bognar, Victor Braga Gondim Teixeira, Rodrigo de Carvalho Moreira, Henry Sznejder, Riad Naim Younes · 2025 · JCO Global Oncology
39. Precision Medicine in Lung Cancer
    Keith M. Kerr, Gavin M. Laing · 2017 · Molecular pathology library
40. Metastatic Brain Disease from Non-small Cell Lung Cancer – Getting Back to the Drawing Board
    Alastair Greystoke, P. Mulvenna · 2018 · Clinical Oncology
41. Development of a Novel One-Step Automated Rapid in situ Hybridization for Anaplastic Lymphoma Kinase Rearrangement Using Non-Contact Alternating-Current Electric-Field Mixing
    Kazuhiro Imai, Shinogu Takashima, Satoshi Fujishima, Tsubasa Matsuo, Shin‐nosuke Watanabe, Hiroshi Nanjo, Yoichi AKAGAMI, Ryuta Nakamura, Kaori Terata, Akiyuki Wakita et al. · 2020 · Pathobiology
42. Molecular Biomarkers in Advanced Non–Small-Cell Lung Cancer: A Rapidly Changing Field
    Robert Pirker · 2017 · Journal of Oncology Practice
43. Targeting the Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-kB) Pathway to Overcome Cisplatin-Resistance in Non-Small Cell Lung Cancer
    Sarah-Louise Ryan · 2019 · Queensland University of Technology
44. Development of an Updated, Standardized, Patient-Centered Outcome Set for Lung Cancer
    Belle Hadewijch de Rooij, Corina J. G. van den Hurk, Veerle R. Smaardijk, Paz Fernández‐Ortega, Arturo Navarro-Martín, Lidia Barberio, Matthias Gückenberger, Severin Schmid, Iris Walraven, Susan Vallow et al. · 2022 · SSRN Electronic Journal
45. Relationship Between Overexpression of EML4-ALK Variant 1 and Inflammatory Moleculars and Immune Mediators Associated with Tumor Progression and Metastasis in BEAS-2B and H2126 Cells
    Yang Chen · 2016 · American Journal of Clinical and Experimental Medicine
46. Resistance of Lung Cancer to Kinase Inhibitors Specific to EGFR or ALK
    Maicol Mancini, Yosef Yarden · 2018 · Resistance to targeted anti-cancer therapeutics
47. Immuntherapien beim fortgeschrittenen NSCLC
    Martin Reck, Wolfgang Schütte, Nicolas Johannes Dickgreber, Niels Reinmuth, Thomas Wehler, Stefanie Morris, Achim Rittmeyer, Wilko Weichert · 2018 · TumorDiagnostik & Therapie
48. Only one step from tailored oncological therapies
    Paweł Adam Krawczyk · 2018 · Nowotwory Journal of Oncology
49. Neoadjuvant PD-1 blockade in non-small cell lung cancer: what else do we need to do?
    Wei Guo, Su Yang, Wentian Zhang, Hecheng Li, Bo Lü · 2018 · Journal of Thoracic Disease
50. Der Einsatz von Checkpoint-Hemmern beim Lungenkarzinom wird breiter
    Justyna K. Rawluk, Cornelius Florian Waller · 2018 · Pneumo News
51. Clinical case of prolonged use of alectinib in the treatment of ALK-positive NSCLC
    Светлана Геннадьевна Багрова, Коломейцева Алина Андреевна, E. V. Trusilova, В. А. Горбунова · 2019 · Meditsinskiy sovet = Medical Council
52. Targeted Therapies For Treatment of Lung Cancer – Recent Advances
    Foziya Khan, Sangram S. Sisodia · 2020 · Pharmaceutical and Biosciences Journal
53. Endothelial growth factor receptor-mutant lung cancer and post-operative care management: one size does not fit all
    JAVERYAH SAFI, Sarah W. Gordon, Peter Lee, Howard Y. Li, Patrick S. Nana-Sinkam, Rachit D. Shah, Ray Wesley Shepherd, Samira Shojaee · 2020 · Annals of Translational Medicine
54. Identification of Key Genes Between Lung Adenocarcinoma and Lung Squamous Cell Carcinoma by Bioinformatics Analysis
    Jinru Xue, MS Yu Yang, MD Bo Jiang, MD Linxue Qian, PhD Xian-Quan Shi · 2020 · Advanced ultrasound in diagnosis and therapy
55. Molecular mechanisms of lung cancer
    О. Э. Лосев, В. Б. Бородулин, Русецкая Наталья Юрьевна, Е. В. Бобылева, Бородулин Ярослав Владимирович · 2021 · Zhurnal «Patologicheskaia fiziologiia i eksperimental`naia terapiia»
56. Investigating a novel function for phosphoserine aminotransferase 1 (PSAT1) in epidermal growth factor receptor (EGFR)-mediated lung tumorigenesis.
    Rumeysa Biyik‐Sit · 2021 · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville)
57. Tabakentwöhnung – die bisher wenig genutzte Chance im ärztlichen Alltag
    Karin Vitzthum, Anil Batra, Wulf Pankow, Matthias Raspe, Alexander Rupp, Stefan Andreas · 2022 · Pneumologie
58. Ensartinib Confers Potent in Vitro and in Vivo Antitumor Activity in Non-Small Cell Lung Cancer Harboring MET Exon 14-Skipping Mutations
    Yang Xia, Rui Jin, Fen Lan, Ting Zhang, Jing Zhao, Yinghui Yu, Zhihua Chen, Songmin Ying, Huahao Shen, Wen Li · 2022 · SSRN Electronic Journal
59. Co-overexpression of STIP1 and Hsp90 correlates with progression and prognosis of lung adenocarcinoma
    Youwen Zhang, Junye Wang, Shucheng Ye, Maoqing Guo, Shenghua Jiang, Wei Li · 2020 · Research Square
60. Liquid Biopsy as an Option for Predictive Testing and Prognosis in Patients with Lung Cancer
    Alvida Qvick, Bianca Stenmark, Jessica Carlsson, Johan Isaksson, Christina Karlsson, Gisela Helenius · 2021 · Research Square
61. Behandlung von schädlichem und abhängigem Tabakkonsum
    Stefan Andreas, Anil Batra, Dörthe Brüggmann, Dieter Geyer, H. Gohlke, Thomas Hering, Andreas Jähne, Julia Jückstöck, Marianne Klein, Daniel Kotz et al. · 2022 · Springer eBooks
62. Ros1 rearrangement in non-small cell lung cancer: attitude towards ros1 test in turkey
    Nalan Akyürek, Büge ÖZ, Handan KAYA, Denız Nart, Emine Baş Bozkurtlar, Sevdegül Munğan, Derya Gümürdülü · 2022 · Journal of Current Pathology
63. A Computer Tomography Radiomics-based model to Predict Survival of Patients with EGFR‑Mutated Non‑small‑cell Lung Cancer
    Chen Huang, Yubin Cao, Lei Zhu, Qunli Xiong, Qin Zhang · 2022 · Research Square
64. Nanoencapsulation of tyrosine kinase inhibitors for oncological therapeutics
    Hoang Lam Nguyen, Ram Krishna Gupta, Tuan Anh Nguyen · 2022 · Elsevier eBooks
65. Targeted Therapies Used in the Treatment of Non–Small-Cell Lung Cancer: An Overview
    Tanuja Yadav, Velisha Mehta, Nilam Bhusare, Meena Chintamaneni, Mayur YC · 2023 · Springer eBooks
66. An epidermal growth factor receptor-mutated lung adenocarcinoma patient with brain lesions resisted to osimertinib monotherapy but achieved more than 4 years of survival in osimertinib plus bevacizumab metronomic treatment
    Jie Liu, Xiao Han, Xiufeng Hu, Yuange He, Yijia Shao, Yanyan Yang, Kai Wang, Yanqiu Zhao · 2024 · Heliyon
67. Traitement ciblé oral contre le cancer du poumon non à petites cellules
    William James Phillips, Natasha B. Leighl, Normand Blais, Paul Wheatley‐Price · 2024 · Canadian Medical Association Journal
68. Treatments Relevant to Individual Cancer Types
    Elaine Vickers · 2024 · Wiley eBooks
69. Clinical Implications of Mixed Response on Prognosis of Non-Small Cell Lung Cancer (Nsclc) Patients Treated with Immunotherapy
    Seyoung Lee, Young Kwang Chae, Taegyu Um, Jeeyeon Lee, Chan Mi Jung, Christopher Shin, Peter Haseok Kim, Monica Yadav, Maria Jose Aguilera Chuchuca, Liam Il‐Young Chung · 2024 · SSRN Electronic Journal
70. Analysis and Comparison of the Trends in Burden of Tracheal, Bronchus, and Lung Cancer in China and Worldwide from 1990 to 2021
    RuPing Zou, Xiaoman Zhang, Yuran Li, Junjie Niu, Mengshi Liu, Min Wu, Jingshuo Zhang · 2024 · SSRN Electronic Journal
71. Driver Genes and Genomic Instability Predict the Incidence and Outcome of Brain Metastases
    Hainan Yang, Weiping Hong, Jie Ding, Weifang Yuan, Hui Ye, Tao Lin, Qingjun Hu, Xin Jin, Lei Wen, Da Liu et al. · 2025 · Current Cancer Drug Targets
72. A Review on Automated Segmentation of Lung Lesions in Chest CT Scans Using Hybrid Approaches
    Raed Hamid Lateef, Ahmed Faeq Hussein · 2025 · Al-Nahrain Journal for Engineering Sciences
73. The biomarkers landscape in lung cancer: implication for diagnosis, prediction, and prognosis
    Fatima Zohra Attouahri, Abdelilah Laraqui, Imane Chaoui, Mohammed Rida Tagajdid, Laïla Benbacer, Boutaina Addoum, Khaoula Errafii‬, Mouna Ababou, Mohammed Attaleb, Khalid Ennibi et al. · 2025 · Elsevier eBooks
74. Additional file 2 of Circular RNA hsa_circ_0050386 suppresses non-small cell lung cancer progression via regulating the SRSF3/FN1 axis
    Chen, Jinbin, Boqi Rao, Zeqin Huang, Xie, Chen, Yu, Yonghui, Binyao Yang, Di Wu, Wang, Dedong, Fuman Qiu, Yifeng Zhou et al. · 2024 · Figshare
75. Additional file 1 of Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer
    Alvida Qvick, Bianca Stenmark, Carlsson, Jessica, Johan Isaksson, Christina Karlsson, Gisela Helenius · 2021 · Figshare
76. Additional file 3 of Circular RNA hsa_circ_0050386 suppresses non-small cell lung cancer progression via regulating the SRSF3/FN1 axis
    Chen, Jinbin, Boqi Rao, Zeqin Huang, Xie, Chen, Yu, Yonghui, Binyao Yang, Wu, Di, Wang, Dedong, Fuman Qiu, Yifeng Zhou et al. · 2024 · Figshare
77. Additional file 1 of Circular RNA hsa_circ_0050386 suppresses non-small cell lung cancer progression via regulating the SRSF3/FN1 axis
    Chen, Jinbin, Boqi Rao, Zeqin Huang, Xie, Chen, Yu, Yonghui, Binyao Yang, Di Wu, Wang, Dedong, Fuman Qiu, Yifeng Zhou et al. · 2024 · Figshare
78. Additional file 4 of Circular RNA hsa_circ_0050386 suppresses non-small cell lung cancer progression via regulating the SRSF3/FN1 axis
    Chen, Jinbin, Boqi Rao, Zeqin Huang, Xie, Chen, Yu, Yonghui, Binyao Yang, Wu, Di, Wang, Dedong, Fuman Qiu, Yifeng Zhou et al. · 2024 · Figshare
79. Breaking resistance barriers: ensartinib as a milestone in anaplastic lymphoma kinase–driven non-small cell lung cancer therapy
    Lohitha Gumma, Bhargavi Gumma, Lakshmi Prasanna Yarrabothula · 2026 · Naunyn-Schmiedeberg s Archives of Pharmacology
80. Ciblage de l'IL-1beta pour améliorer l'efficacité de la chimio-immunothérapie dans le cancer
    Anaïs Perrichet · 2024 · theses.fr (ABES)
81. Optimizing Lung Cancer Diagnosis through Gray Relational Analysis: A Data-Driven Approach
    Chandrasekar Raja · 2026 · Computer Science Engineering and Technology
82. Global burden of multiple myeloma(1990–2021) and projections up to 2035: a methodical analysis leveraging the global burden of disease 2021 study and Mendelian randomization
    Run Qu, Xin Zhang, Jing Zou, Jinghua Ning, Yanhong Zhao, Yi Liang, Yuzhe Zhang · 2026 · Journal of the Egyptian National Cancer Institute
83. Evaluation of EGFR Mutation Testing Concordance Between Next‐Generation Sequencing and Biocartis Idylla Console in NSCLC
    Vidusha Wijesinghe, Mary Jones, Leonie Wheeldon · 2026 · Cytopathology
84. Clinical outcomes of KRAS G12C versus non-G12C mutant NSCLC treated with immunotherapy: a multicentre real-world study
    Laura Masfarré, A.S.D.F.M. Parreira, N. Castro Unanua, Claudia Miquel, Nil Navarro-Gorro, Raquel Marse Fabregat, Cristina Gómez Bellvert, Amaia Ario Fernandez, Maite Martínez Aguillo, Hugo Arasanz et al. · 2026 · Lung Cancer
85. Foundations of Cancer and Parenteral Oncology Therapies
    Fernando Moreira · 2026 · Advances in computational intelligence and robotics book series